Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)

1 juillet 2026 mis à jour par: University of Aarhus

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)

Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine.

Furosemide is a commonly used water-removing medicine that is given into a vein to treat fluid overload. It can be given in different ways. One way is as a continuous infusion, where the medicine is given slowly over time through a pump. Another way is as repeated injections given several times a day. It is not known whether one of these ways is better than the other for removing excess fluid in people with acute heart failure.

The purpose of this study is to compare two ways of giving furosemide into a vein: Continuous infusion started with an initial extra dose, and bolus injections given three times a day. About 436 adults admitted to hospitals in Denmark with acute heart failure and fluid overload will take part. Participants will be randomly assigned to one of the two treatment groups. This means that chance will decide which treatment method each participant receives.

The main thing the researchers will measure is how much body weight participants lose about 3 days after randomization. Weight loss is used as a measure of how much excess fluid has been removed.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

INFUSE-AHF is an investigator-initiated, multicentre, open-label, pragmatic, randomized clinical trial conducted at hospitals in Denmark. The trial compares two commonly used ways of administering intravenous furosemide in adults hospitalized with acute heart failure and volume overload: Continuous infusion preceded by a loading dose, and bolus injections administered three times a day.

The rationale for the trial is that intravenous loop diuretics are standard treatment for acute heart failure with volume overload, but the optimal method of administration remains uncertain. Previous evidence has not established whether continuous infusion or bolus injections are superior. In addition, continuous infusion without an initial loading dose may delay achievement of effective plasma concentrations. The INFUSE-AHF trial, therefore, specifically evaluates continuous infusion preceded by a loading dose compared with bolus injections three times a day.

The trial includes three phases. The inclusion phase starts when a potential participant is identified during hospitalization and ends when the first dose of trial treatment is administered. The treatment phase starts with the first administration of intravenous furosemide and continues until the last weight measurement on the morning of Day 4. The follow-up phase starts after the treatment phase and continues until 30 days after the first injection.

Participants are randomized in a 1:1 ratio to one of the two treatment strategies. In the continuous infusion group, an initial loading dose is administered immediately before the infusion is started. In the bolus group, furosemide is administered as bolus injections three times a day, and the first bolus includes an additional dose to mirror the loading dose strategy. Daily intravenous furosemide doses are determined according to the participant's oral loop diuretic dose at admission using a predefined dosing algorithm. During the first part of the treatment period, doses are protocolized. On the morning of Day 3, the treating clinician may increase the dose, maintain the same dose, or stop intravenous treatment according to the protocol and the participant's clinical status.

Approximately 436 participants will be enrolled. The primary endpoint is net weight loss 3 days, equivalent to approximately 72 hours, after randomization. Secondary endpoints include net weight loss 2 days after randomization, change in dyspnea on a Visual Analog Scale 3 days after randomization, days alive out of hospital to Day 30, and length of hospital stay. Safety endpoints include acute kidney injury, severe electrolyte disturbances, incidents, and side effects.

Type d'étude

Interventionnel

Inscription (Estimé)

436

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

  • Danemark
      • Randers, Danemark, 8930
        • Recrutement
        • Department of Medicine, Randers Regional Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Clinical diagnosis of acute heart failure with volume overload
  • At least 1 sign of volume overload
  • Anticipated intravenous furosemide treatment for at least 3 days
  • Age 18 years or older

Exclusion Criteria:

  • Shock
  • Patient requiring treatment with inotropes or vasopressors
  • Current or planned use of renal replacement therapy or ultrafiltration
  • Patient with a renal transplant
  • Patients who are pregnant or breastfeeding
  • Severe hypokalaemia, defined as potassium less than 2.5 mmol/L, or severe hyponatremia, defined as sodium less than 125 mmol/L
  • Allergy to furosemide and its components

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Continuous infusion preceded by a loading dose
Participants receive intravenous furosemide administered as a continuous infusion preceded by an initial loading dose. The loading dose is administered immediately before initiation of the infusion. Daily intravenous furosemide doses are determined according to the participant's oral loop diuretic dose at hospital admission using a predefined dosing algorithm.
Médicament: Intravenous furosemide continuous infusion
Intravenous furosemide administered as a continuous infusion preceded by a loading dose. Daily intravenous furosemide doses are determined according to the participant's oral loop diuretic dose at hospital admission using a predefined dosing algorithm.
Autres noms:
  • Furosemide infusion
Expérimental: Bolus injections three times a day
Participants receive intravenous furosemide administered as bolus injections three times a day. The first bolus injection includes an additional dose to mirror the loading dose strategy used in the continuous infusion group. Daily intravenous furosemide doses are determined according to the participant's oral loop diuretic dose at hospital admission using a predefined dosing algorithm.
Médicament: Intravenous furosemide bolus injections
Intravenous furosemide administered as bolus injections three times a day. The first bolus injection includes an additional dose to mirror the loading dose strategy used in the continuous infusion group. Daily intravenous furosemide doses are determined according to the participant's oral loop diuretic dose at hospital admission using a predefined dosing algorithm.
Autres noms:
  • Furosemide bolus injections

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Net weight loss 3 days after randomization
Délai: From randomization to approximately 72 hours
Net change in body weight from randomization to the morning of Day 4, corresponding to approximately 72 hours after randomization.
From randomization to approximately 72 hours

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Net weight loss 2 days after randomization
Délai: From randomization to approximately 48 hours
Net change in body weight from randomization to the morning of Day 3, corresponding to approximately 48 hours after randomization.
From randomization to approximately 48 hours
Change in dyspnea 3 days after randomization
Délai: From randomization to approximately 72 hours
Change in dyspnea assessed using a Visual Analogue Scale from randomization to the morning of Day 4, corresponding to approximately 72 hours after randomization.
From randomization to approximately 72 hours
Days alive out of hospital to Day 30
Délai: From randomization to 30 days
Number of days alive and out of hospital from randomization to Day 30.
From randomization to 30 days
Length of hospital stay
Délai: From randomization up to 30 days
Duration of the index hospital admission.
From randomization up to 30 days

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Net weight loss 1 day after randomization
Délai: From randomization to approximately 24 hours
Net change in body weight from randomization to the morning of Day 2, corresponding to approximately 24 hours after randomization.
From randomization to approximately 24 hours
Change in dyspnea 1 day after randomization
Délai: From randomization to approximately 24 hours
Change in dyspnea assessed using a Visual Analogue Scale from randomization to the morning of Day 2, corresponding to approximately 24 hours after randomization.
From randomization to approximately 24 hours
Change in dyspnea 2 days after randomization
Délai: From randomization to approximately 48 hours
Change in dyspnea assessed using a Visual Analogue Scale from randomization to the morning of Day 3, corresponding to approximately 48 hours after randomization.
From randomization to approximately 48 hours
Death from any cause after 30 days
Délai: From randomization to 30 days
All-cause mortality assessed 30 days after randomization.
From randomization to 30 days
Rehospitalization from any cause after 30 days
Délai: From randomization to 30 days
Rehospitalization from any cause assessed 30 days after randomization.
From randomization to 30 days
Acute kidney injury
Délai: From randomization to approximately 72 hours
Proportion of participants with acute kidney injury grade 2 or higher as defined by KDIGO criteria during the treatment phase.
From randomization to approximately 72 hours
Severe electrolyte disturbances
Délai: From randomization to approximately 72 hours
Proportion of participants with severe hypokalaemia, severe hyponatremia, or severe hypernatremia, defined as potassium less than 2.5 mmol/L, sodium less than 125 mmol/L, or sodium greater than 155 mmol/L.
From randomization to approximately 72 hours
Incidents and side effects
Délai: From randomization to 30 days
Treatment-emergent serious adverse events, including incidents and side effects.
From randomization to 30 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Aarhus

Collaborateurs

Central Denmark Region

Les enquêteurs

  • Directeur d'études: Esben Merrild, MD, Department of Medicine, Randers Regional Hospital
  • Chaise d'étude: Bo Løfgren, MD PhD, Department of Medicine, Randers Regional Hospital
  • Chaise d'étude: Henrik Birn, MD PhD DMSc, Department of Renal Medicine, Aarhus University Hospital
  • Chaise d'étude: Kasper G Lauridsen, MD PhD, Department of Medicine, Randers Regional Hospital
  • Chaise d'étude: Christian B Poulsen, MD PhD, Private Organization

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 juin 2026

Achèvement primaire (Estimé)

1 septembre 2027

Achèvement de l'étude (Estimé)

1 octobre 2027

Dates d'inscription aux études

Première soumission

28 avril 2026

Première soumission répondant aux critères de contrôle qualité

5 mai 2026

Première publication (Réel)

11 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 juillet 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • INFUSEAHF
  • 2025-523589-26-00 (Ctis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data may be made available after publication of the main trial results, subject to approval by the Steering Committee and in accordance with applicable data protection legislation. All trial data will be pseudo-anonymized and stored for 25 years after the end of the trial in accordance with Danish law and GDPR requirements. Data sharing will be considered on a case-by-case basis for scientifically sound research proposals that do not conflict with ongoing or planned analyses, intellectual property considerations, or the governance and objectives of the trial. Requests for data access must be submitted to the Scientific Lead or Coordinating Investigator and will be evaluated by the Steering Committee based on methodological quality, feasibility, and compatibility with the scientific, ethical, and strategic framework of the trial. There is no obligation for unrestricted, automatic, or indefinite data sharing.

Délai de partage IPD

After publication of the main trial results. Data will be considered available on a case-by-case basis, and there is no predefined end date for availability.

Critères d'accès au partage IPD

Requests must be submitted to the Scientific Lead or Coordinating Investigator and will be evaluated by the Steering Committee. Access may be granted for scientifically sound research proposals that do not conflict with ongoing or planned analyses, intellectual property considerations, or the governance and objectives of the trial. Requests will be evaluated based on methodological quality, feasibility, and compatibility with the scientific, ethical, and strategic framework of the trial.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner